Use of Aptar Digital Health's Respiratory Disease Management Platform for Asthma

* Age ≥ 16 years * Utilization of asthma controller therapy: inhaled corticosteroids (ICS), long-acting β2-agonists (LABAs) and/or fixed combination therapies of LABA and ICS (medium to high-dose ICS/LABA therapy) * Use of metered dose inhaler (MDI) and / or dry powder dose inhaler (DPI) list of compatible controller medications is noted in section 9.2. * FeNO ≥ 35 ppb during the baseline assessment. * Primary respiratory diagnosis of asthma * Uncontrolled, moderate-to-severe asthma. This is defined by an ACQ-5 ≥1.5 during the baseline assessment. * Current non-smoker. A 'current non-smoker' has never smoked or has quit smoking for at least 12 months. This is inclusive of all types of smoking: i.e. e-cigarettes/vaping. * Capable of giving signed informed consent, which includes compliance with requirements and restrictions listed in consent form and protocol. * Subject understands and is willing, able, and likely to comply with study procedures and restrictions * Willingness to participate in this study and to use the Aptar Digital Health technology * Willingness to share information / data with Aptar Digital Health (through informed consent) Access to technology * Access to a smartphone (requirements Android: ≥ 11 or iOS: ≥ 15) * Ability to use smartphone (smartphone usability assessment to be provided by Aptar Digital Health) * Access to the UK app store or google play store for application download. ● Access to a current email account * Access to data / Wi-Fi Exclusion …